Temozolomide in Veterinary Oncology: Oral Alkylator and Evidence Boundary

temozolomide is covered as triazene antineoplastic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Triazene antineoplastic agents; hazardous antineoplastic medicine. Temozolomide.

Temozolomide.

Temozolomide is an imidazotetrazine related to dacarbazine. It generates methylating species that damage DNA and can cross the blood-brain barrier.

Veterinary references discuss selected brain tumours, melanoma, sarcoma and lymphoma settings. Choice depends on histology, anatomic site, molecular features when relevant, prior therapy and realistic goals.

Veterinary references discuss selected brain tumours, melanoma, sarcoma and lymphoma settings. Choice depends on histology, anatomic site, molecular features when relevant, prior therapy and realistic goals.

Oral hazardous chemotherapy under a veterinary oncology protocol

Evidence is limited, heterogeneous and often combines temozolomide with another treatment. Its human oncology role must not be imported wholesale into dogs or cats, and brain penetration is not proof of clinical benefit for every CNS tumour.

Nausea, vomiting, diarrhoea and mild-to-moderate marrow suppression are recognised. Capsules are hazardous medicine and require pharmacy-quality dispensing, secure storage and an exposure plan.

Concurrent marrow suppressants and radiation can alter tolerance. Home handling, missed doses, vomiting after administration and bodily-waste precautions must follow the prescribing clinic, not internet instructions.

No FDA-approved canine or feline oncology indication was established for this medicine in this audit. In the United States, veterinary oncology use of an approved human or animal formulation is extra-label and must occur under a veterinarian within AMDUCA conditions and a valid VCPR.

Multi-region specialist use; product availability, extra-label prescribing law and pharmacy handling vary by jurisdiction.

The veterinarian plans blood counts and organ testing around the chosen protocol and tracks neurologic status or tumour-specific imaging. Caregivers should use the written hazardous-drug plan and report fever, marked lethargy, bleeding, persistent gastrointestinal signs or neurologic deterioration.